Repatha ® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

Study Showed Lowering LDL-C With Repatha Did Not Impair Cognition Results From One of the Largest Cognitive Function Trials Support Safety Profile of Repatha THOUSAND OAKS, Calif., Aug. 16, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER). The study demonstrated that Repatha was non-inferior to placebo, with no significant difference in cognitive function between the Repatha and placebo-treated groups. ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news